R-Crio | Stem Cells

r-crio.com

R-Crio S.A. is a company specialized in cryopreservation of adult stem cells from the pulp of deciduous (baby) teeth. R-Crio was founded in 2013 by Dr. José Ricardo Muniz Ferreira, after a decade of research involving biomaterials and stem cells in regenerative medicine and tissue bioengineering in collaboration with researchers from high-ranking universities.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

SYSMEX AND THINKCYTE HAVE ENTERED INTO AN AGREEMENT FOR JOINT DEVELOPMENT AND CAPITAL ALLIANCE

Sysmex Corporation | May 17, 2021

news image

Sysmex Corporation and ThinkCyte, Inc. announced today the signing of joint development and investment agreements for the commercialization of an AI-based cell analysis technology in May 2021. The development of novel testing and diagnostic technologies of high clinical utility is being pursued to improve the precision of diagnoses and maximize treatment as healthcare becomes more accurate and personalized at an increased pace - in combination with the advancement of technology. M...

Read More

INDUSTRIAL IMPACT

SUTRO BIOPHARMA AND TASLY BIOPHARMACEUTICALS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR STRO-002 IN GREATER CHINA

Sutro Biopharma | December 28, 2021

news image

Sutro Biopharma, Inc. a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced an exclusive license agreement with Tasly Biopharmaceuticals Co., Ltd. a holding subsidiary of Tasly Pharmaceutical Group Co., Ltd. for the development and commercialization of STRO-002 in Greater China, consisting of mainland China, Hong Kong, Macau and Ta...

Read More

BIOTECH LIFE SCIENCES INITIATES NEW STUDY OF ANTI-AGING FORMULAS IN HELPING COVID-19 POST-VIRAL FATIGUE AND CHRONIC FATIGUE SYNDROME

BioTech Life Sciences | August 06, 2020

news image

BioTech Life Sciences (BioTech – https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.).The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-V...

Read More

CELL AND GENE THERAPY

BEIGENE INITIATES FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL OF INVESTIGATIONAL TYK2 INHIBITOR BGB-23339

BeiGene | November 23, 2021

news image

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists. TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psor...

Read More
news image

CELL AND GENE THERAPY

SYSMEX AND THINKCYTE HAVE ENTERED INTO AN AGREEMENT FOR JOINT DEVELOPMENT AND CAPITAL ALLIANCE

Sysmex Corporation | May 17, 2021

Sysmex Corporation and ThinkCyte, Inc. announced today the signing of joint development and investment agreements for the commercialization of an AI-based cell analysis technology in May 2021. The development of novel testing and diagnostic technologies of high clinical utility is being pursued to improve the precision of diagnoses and maximize treatment as healthcare becomes more accurate and personalized at an increased pace - in combination with the advancement of technology. M...

Read More
news image

INDUSTRIAL IMPACT

SUTRO BIOPHARMA AND TASLY BIOPHARMACEUTICALS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR STRO-002 IN GREATER CHINA

Sutro Biopharma | December 28, 2021

Sutro Biopharma, Inc. a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, announced an exclusive license agreement with Tasly Biopharmaceuticals Co., Ltd. a holding subsidiary of Tasly Pharmaceutical Group Co., Ltd. for the development and commercialization of STRO-002 in Greater China, consisting of mainland China, Hong Kong, Macau and Ta...

Read More
news image

BIOTECH LIFE SCIENCES INITIATES NEW STUDY OF ANTI-AGING FORMULAS IN HELPING COVID-19 POST-VIRAL FATIGUE AND CHRONIC FATIGUE SYNDROME

BioTech Life Sciences | August 06, 2020

BioTech Life Sciences (BioTech – https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.).The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-V...

Read More
news image

CELL AND GENE THERAPY

BEIGENE INITIATES FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL OF INVESTIGATIONAL TYK2 INHIBITOR BGB-23339

BeiGene | November 23, 2021

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists. TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psor...

Read More